DGIdb - CAPECITABINE Drug Record

CAPECITABINE chembl:CHEMBL1773 ApprovedAntineoplasticImmunotherapy

Alternate Names:

XELODA
RO-09-1978000
CAPECITABINE
RO-091978000
XELODA®
CAPECITABINA
CAPECITABINUM
RO-09-1978-000
PENTYL 1-(5-DEOXY-BETA-D-RIBOFURANOSYL)-5-FLUORO-1,2-DIHYDRO-2-OXO-4-PYRIMIDINECARBAMATE
(1-(5-DEOXY-BETA-D-RIBOFURANOSYL)-5-FLUORO-1,2-DIHYDRO-2-OXO-4-PYRIMIDINYL)-CARBAMIC ACID PENTYL ESTER
PENTYL [1-(5-DEOXY-BETA-D-RIBOFURANOSYL)-5-FLUORO-2-OXO-1,2-DIHYDROPYRIMIDIN-4-YL]CARBAMATE
PENTYL [1-(3,4-DIHYDROXY-5-METHYL-OXOLAN-2-YL)-5-FLUORO-2-OXO-PYRIMIDIN-4-YL]AMINOFORMATE
CAPECITABIN
chemidplus:154361-50-9
drugbank:01101
chembl:CHEMBL1773
pubchem.compound:60953
rxcui:194000

Drug Info:

(6 More Sources)

Publications:

Sharon E et al., 2010, Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine., Head Neck Oncol
von Minckwitz et al., 2009, Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study., J. Clin. Oncol.
Geyer et al., 2006, Lapatinib plus capecitabine for HER2-positive advanced breast cancer., N. Engl. J. Med.
Grellety et al., 2016, A clinical case of invasive lobular breast carcinoma with ERBB2 and CDH1 mutations presenting a dramatic response to anti-HER2-directed therapy., Ann. Oncol.
Bartsch et al., 2007, Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer., J. Clin. Oncol.
Baselga et al., 2016, Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer., Clin. Cancer Res.
Kwak et al., 2015, Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer., Cancer Discov
Saura et al., 2014, Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer., J. Clin. Oncol.
Pellicer M et al., 2017, Identification of new SNPs associated with severe toxicity to capecitabine., Pharmacol Res
Stepanova et al., 2005, [Thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in soft-tissue sarcoma versus capecitabine potential]., Vopr Onkol
Caudle et al., 2013, Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing., Clin. Pharmacol. Ther.
Fischel et al., 2006, Synergistic cytotoxic interaction in hormone-refractory prostate cancer with the triple combination docetaxel-erlotinib and 5-fluoro-5'-deoxyuridine., Anticancer Drugs
Carlini et al., 2005, UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan., Clin. Cancer Res.
Li et al., 2005, Rapid quantitation of plasma 2'-deoxyuridine by high-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometry and its application to pharmacodynamic studies in cancer patients., J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Patel et al., 2004, Enzyme expression profiles suggest the novel tumor-activated fluoropyrimidine carbamate capecitabine (Xeloda) might be effective against papillary thyroid cancers of children and young adults., Cancer Chemother. Pharmacol.
Eliason et al., 2004, Potential for predicting toxicity and response of fluoropyrimidines in patients., Curr Drug Targets
Tsunoda A et al., 2011, Associations of various gene polymorphisms with toxicity in colorectal cancer patients receiving oral uracil and tegafur plus leucovorin: a prospective study., Ann Oncol
Ichikawa W et al., 2006, Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen., Clin Cancer Res
Meulendijks D et al., 2016, Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicity., Int J Cancer
Falvella FS et al., 2015, DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan., Br J Clin Pharmacol
Amstutz U et al., 2015, Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy., Clin Cancer Res
Offer SM et al., 2014, microRNAs miR-27a and miR-27b directly regulate liver dihydropyrimidine dehydrogenase expression through two conserved binding sites., Mol Cancer Ther
Sebio A et al., 2015, EGFR ligands and DNA repair genes: genomic predictors of complete response after capecitabine-based chemoradiotherapy in locally advanced rectal cancer., Pharmacogenomics J
Kim JG et al., 2009, Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin., Cancer Chemother Pharmacol
Sclafani et al., 2014, TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial., J. Natl. Cancer Inst.
Joerger M et al., 2015, Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy., Cancer Chemother Pharmacol
Yang et al., 2012, Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer., Cancer Res.
Tol J et al., 2009, BRAF mutation in metastatic colorectal cancer., N Engl J Med
Jennings BA et al., 2013, Evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidines., PLoS One
Custodio A et al., 2014, Pharmacogenetic predictors of outcome in patients with stage II and III colon cancer treated with oxaliplatin and fluoropyrimidine-based adjuvant chemotherapy., Mol Cancer Ther
van Huis-Tanja LH et al., 2015, Clinical validation study of genetic markers for capecitabine efficacy in metastatic colorectal cancer patients., Pharmacogenet Genomics
Meulendijks D et al., 2017, Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies., Pharmacogenomics J
Yang YC et al., 2017, Association of thymidylate synthase polymorphisms with the tumor response to preoperative chemoradiotherapy in rectal cancer: a systematic review and meta-analysis., Pharmacogenomics J
Gao J et al., 2013, Polymorphism of TS 3'-UTR predicts survival of Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel., Clin Transl Oncol
Kim SR et al., 2010, Genetic polymorphisms associated with 5-Fluorouracil-induced neurotoxicity., Chemotherapy
Ruzzo A et al., 2008, Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy., Pharmacogenomics J
Hamzic S et al., 2017, Novel Genetic Variants in Carboxylesterase 1 Predict Severe Early-Onset Capecitabine-Related Toxicity., Clin Pharmacol Ther
Dong N et al., 2012, Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine., J Cancer Res Clin Oncol
Loganayagam A et al., 2013, Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity., Br J Cancer
Caronia D et al., 2011, A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome., Clin Cancer Res
Ribelles N et al., 2008, A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression., Curr Drug Metab
Yousef AM et al., 2018, The association of polymorphisms in folate-metabolizing genes with response to adjuvant chemotherapy of colorectal cancer., Cancer Chemother Pharmacol
Nahid NA et al., 2018, DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer., Cancer Chemother Pharmacol
Roberto M et al., 2017, Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine., Eur J Clin Pharmacol
Borro M et al., 2017, Pre-treatment assay of 5-fluorouracil degradation rate (5-FUDR) to improve prediction of 5-fluorouracil toxicity in gastro-esophageal cancer., Oncotarget
Romiti A et al., 2016, The TYMS-TSER polymorphism is associated with toxicity of low-dose capecitabine in patients with advanced gastrointestinal cancer., Anticancer Drugs
Mazzuca F et al., 2016, Pre-treatment evaluation of 5-fluorouracil degradation rate: association of poor and ultra-rapid metabolism with severe toxicity in a colorectal cancer patients cohort., Oncotarget
Chaturvedi P et al., 2015, Relationship of MTHFR and NQO1 Pharmacogenetics and Chemotherapy Clinical Outcomes in Breast Cancer Patients., Biochem Genet
Cecchin E et al., 2015, MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin., Pharmacogenomics J
van Huis-Tanja LH et al., 2013, MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer., Pharmacogenet Genomics
Lee KH et al., 2013, Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer., Cancer Chemother Pharmacol
Kristensen MH et al., 2010, Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients., J Int Med Res
Henríquez-Hernández LA et al., 2010, Distribution of TYMS, MTHFR, p53 and MDR1 gene polymorphisms in patients with breast cancer treated with neoadjuvant chemotherapy., Cancer Epidemiol
Boige V et al., 2010, Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05., J Clin Oncol
Gusella M et al., 2009, Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer., Br J Cancer
Schwab M et al., 2008, Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group., J Clin Oncol
Sharma R et al., 2008, Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients., Clin Cancer Res
Capitain O et al., 2008, The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer., Pharmacogenomics J
Wang L et al., 2015, Association between Polymorphisms in Vascular Endothelial Growth Factor Gene and Response to Chemotherapies in Colorectal Cancer: A Meta-Analysis., PLoS One
Hansen TF et al., 2011, The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer., Pharmacogenomics J
Giovannetti E et al., 2011, Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy., Pharmacogenomics
Gonzalez-Haba E et al., 2010, ABCB1 gene polymorphisms are associated with adverse reactions in fluoropyrimidine-treated colorectal cancer patients., Pharmacogenomics
Zhao J et al., 2014, Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer., Med Oncol
McLeod HL et al., 2010, Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741., J Clin Oncol
Pander J et al., 2015, Genome Wide Association Study for Predictors of Progression Free Survival in Patients on Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in First-Line Therapy of Metastatic Colorectal Cancer., PLoS One

CAPECITABINE MIR27A

Interaction Score: 4.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26804235 25782327 25655103 24401318

Sources:
PharmGKB
CAPECITABINE ENOSF1

Interaction Score: 2.4

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28347776 27995989 27001118 23263912 20714149 17549067

Sources:
PharmGKB
CAPECITABINE CDA

Interaction Score: 1.72

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28347776 24167597 23736036 21325291 18473752

Sources:
PharmGKB
CAPECITABINE MIR2054

Interaction Score: 1.72

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
CAPECITABINE CES1P1

Interaction Score: 1.72

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28139840

Sources:
PharmGKB
CAPECITABINE ADCY2

Interaction Score: 1.72

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25815774

Sources:
PharmGKB
CAPECITABINE MTHFR

Interaction Score: 1.44

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29845393 29134491 27995989 27864592 27738344 27557140 26967565 26014925 25331073 24167597 23736036 23407049 23314736 20819423 20638924 20385995 19384296 18299612 18245544 17700593

Sources:
PharmGKB
CAPECITABINE UMPS

Interaction Score: 1.37

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28347776 20647221 16818689

Sources:
PharmGKB
CAPECITABINE SLC22A7

Interaction Score: 1.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28347776

Sources:
PharmGKB
CAPECITABINE DPYD

Interaction Score: 0.95

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16279094 23988873

Sources:
NCI CIViC FDA
CAPECITABINE MGAT4A

Interaction Score: 0.86

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26222057

Sources:
PharmGKB
CAPECITABINE DLG5

Interaction Score: 0.86

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
CAPECITABINE EXO1

Interaction Score: 0.86

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
CAPECITABINE CDH1

Interaction Score: 0.69

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Lapatinib + Capecitabine

Indication/Tumor Type breast cancer

Response Type sensitive

PMIDs:
26487584

Sources:
JAX-CKB
CAPECITABINE AREG

Interaction Score: 0.69

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25026457

Sources:
PharmGKB
CAPECITABINE HLA-G

Interaction Score: 0.57

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
CAPECITABINE REV3L

Interaction Score: 0.57

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
CAPECITABINE TYMP

Interaction Score: 0.57

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24167597

Sources:
PharmGKB
CAPECITABINE SELE

Interaction Score: 0.43

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24980946

Sources:
PharmGKB
CAPECITABINE TYMS

Interaction Score: 0.42

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Thymidylate synthase inhibitor

Direct Interaction yes

PMIDs:
16926630 15709193 15866500 11752352 15132128 15134221

Sources:
ClearityFoundationBiomarkers ClearityFoundationClinicalTrial ChemblInteractions
CAPECITABINE CES1

Interaction Score: 0.31

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28139840

Sources:
PharmGKB
CAPECITABINE TYMSOS

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25677447

Sources:
PharmGKB
CAPECITABINE ERCC1

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25026457

Sources:
PharmGKB
CAPECITABINE CYP1A1

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22426923

Sources:
PharmGKB
CAPECITABINE VEGFA

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25955730 20125120

Sources:
PharmGKB
CAPECITABINE ERBB2

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type breast cancer

combination therapy Capecitabine + Neratinib

combination therapy ARRY-380 + Capecitabine + Trastuzumab

PMIDs:
20504363 19289619 17192538 26487584 17679724 26920887 26432108 25287822

Sources:
JAX-CKB CIViC
CAPECITABINE ABCG2

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24338217 20530282

Sources:
PharmGKB
CAPECITABINE BRAF

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22180495 19571295

Sources:
CIViC
CAPECITABINE CYP19A1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
CAPECITABINE PTGS2

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19219602

Sources:
PharmGKB
CAPECITABINE PIK3CA

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Lapatinib + Capecitabine

Indication/Tumor Type Her2-receptor positive breast cancer

Response Type decreased response

PMIDs:
26920887

Sources:
JAX-CKB CIViC
CAPECITABINE MET

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

Response Type resistant

Evidence Type Actionable

Approval Status Clinical Study

PMIDs:
26432108

Sources:
JAX-CKB
CAPECITABINE ABCB1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22026922 21142915

Sources:
PharmGKB
CAPECITABINE PTEN

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
CAPECITABINE KRAS

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Bevacizumab + Capecitabine

Indication/Tumor Type colorectal cancer

Response Type predicted – sensitive

PMIDs:
None found

Sources:
JAX-CKB
CAPECITABINE TP53

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24957073

Sources:
CIViC

NCI: CAPECITABINE
- Version: 14-September-2017
Alternate Names:

C1794 NCI drug code

Drug Info:

Publications:

Stepanova et al., 2005, [Thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in soft-tissue sarcoma versus capecitabine potential]., Vopr Onkol

PharmGKB: capecitabine

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Custodio A et al., 2014, Pharmacogenetic predictors of outcome in patients with stage II and III colon cancer treated with oxaliplatin and fluoropyrimidine-based adjuvant chemotherapy., Mol Cancer Ther

Hamzic S et al., 2017, Novel Genetic Variants in Carboxylesterase 1 Predict Severe Early-Onset Capecitabine-Related Toxicity., Clin Pharmacol Ther

Dong N et al., 2012, Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine., J Cancer Res Clin Oncol

JAX-CKB: Capecitabine

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Grellety et al., 2016, A clinical case of invasive lobular breast carcinoma with ERBB2 and CDH1 mutations presenting a dramatic response to anti-HER2-directed therapy., Ann. Oncol.

Bartsch et al., 2007, Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer., J. Clin. Oncol.

Kwak et al., 2015, Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer., Cancer Discov

CIViC: CAPECITABINE

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Tol J et al., 2009, BRAF mutation in metastatic colorectal cancer., N Engl J Med

Yang et al., 2012, Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer., Cancer Res.

Sharon E et al., 2010, Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine., Head Neck Oncol

TTD: Capecitabine
- Version: 2020.06.01
Alternate Names:

D00HCQ TTD Drug ID

Drug Info:

Publications:
ChemblInteractions: CHEMBL1773
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1773
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ClearityFoundationBiomarkers: CAPECITABINE
- Version: 26-July-2013
Alternate Names:

Drug Info:

Publications:
ClearityFoundationClinicalTrial: CAPECITABINE
- Version: 15-June-2013
Alternate Names:

Drug Info:

Publications:
FDA: Capecitabine
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:

combination therapy	Lapatinib + Capecitabine
Indication/Tumor Type	breast cancer
Response Type	sensitive

Mechanism of Interaction	Thymidylate synthase inhibitor
Direct Interaction	yes

Response Type	resistant
Evidence Type	Actionable
Approval Status	Clinical Study

combination therapy	Bevacizumab + Capecitabine
Indication/Tumor Type	colorectal cancer
Response Type	predicted – sensitive

CAPECITABINE Drug Record

CAPECITABINE chembl:CHEMBL1773 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26804235 25782327 25655103 24401318

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28347776 27995989 27001118 23263912 20714149 17549067

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28347776 24167597 23736036 21325291 18473752

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28139840

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25815774

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29845393 29134491 27995989 27864592 27738344 27557140 26967565 26014925 25331073 24167597 23736036 23407049 23314736 20819423 20638924 20385995 19384296 18299612 18245544 17700593

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28347776 20647221 16818689

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28347776

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16279094 23988873

Sources: NCI CIViC FDA

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26222057

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Lapatinib + Capecitabine Indication/Tumor Type breast cancer Response Type sensitive

PMIDs: 26487584

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25026457

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24167597

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24980946

Interaction Types & Directionality:

n/a

PMIDs:
26804235 25782327 25655103 24401318

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
28347776 27995989 27001118 23263912 20714149 17549067

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
28347776 24167597 23736036 21325291 18473752

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
28139840

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25815774

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29845393 29134491 27995989 27864592 27738344 27557140 26967565 26014925 25331073 24167597 23736036 23407049 23314736 20819423 20638924 20385995 19384296 18299612 18245544 17700593

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
28347776 20647221 16818689

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
28347776

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
16279094 23988873

Sources:
NCI CIViC FDA

Interaction Types & Directionality:

n/a

PMIDs:
26222057

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Lapatinib + Capecitabine

Indication/Tumor Type breast cancer

Response Type sensitive

PMIDs:
26487584

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
25026457

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24167597

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24980946

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Thymidylate synthase inhibitor

Direct Interaction yes

PMIDs:
16926630 15709193 15866500 11752352 15132128 15134221

Sources:
ClearityFoundationBiomarkers ClearityFoundationClinicalTrial ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
28139840

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25677447

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25026457

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22426923

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25955730 20125120

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type breast cancer

combination therapy Capecitabine + Neratinib

combination therapy ARRY-380 + Capecitabine + Trastuzumab

PMIDs:
20504363 19289619 17192538 26487584 17679724 26920887 26432108 25287822